- Home
- SHIP vs LCTX Comparison
SHIP vs LCTX Comparison
Compare SHIP & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHIP
- LCTX
- Stock Information
- Founded
- SHIP 2008
- LCTX 1990
- Country
- SHIP Greece
- LCTX United States
- Employees
- SHIP N/A
- LCTX N/A
- Industry
- SHIP Marine Transportation
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SHIP Consumer Discretionary
- LCTX Health Care
- Exchange
- SHIP Nasdaq
- LCTX Nasdaq
- Market Cap
- SHIP 114.3M
- LCTX 107.3M
- IPO Year
- SHIP 2007
- LCTX N/A
- Fundamental
- Price
- SHIP $6.23
- LCTX $0.66
- Analyst Decision
- SHIP Strong Buy
- LCTX Strong Buy
- Analyst Count
- SHIP 1
- LCTX 5
- Target Price
- SHIP $11.00
- LCTX $4.20
- AVG Volume (30 Days)
- SHIP 94.4K
- LCTX 1.1M
- Earning Date
- SHIP 05-27-2025
- LCTX 05-13-2025
- Dividend Yield
- SHIP 10.59%
- LCTX N/A
- EPS Growth
- SHIP 48.17
- LCTX N/A
- EPS
- SHIP 1.26
- LCTX N/A
- Revenue
- SHIP $153,372,000.00
- LCTX $9,557,000.00
- Revenue This Year
- SHIP N/A
- LCTX N/A
- Revenue Next Year
- SHIP $21.30
- LCTX $232.66
- P/E Ratio
- SHIP $4.93
- LCTX N/A
- Revenue Growth
- SHIP 17.53
- LCTX 19.42
- 52 Week Low
- SHIP $4.78
- LCTX $0.37
- 52 Week High
- SHIP $12.80
- LCTX $1.15
- Technical
- Relative Strength Index (RSI)
- SHIP 57.16
- LCTX 66.01
- Support Level
- SHIP $5.81
- LCTX $0.48
- Resistance Level
- SHIP $6.54
- LCTX $0.70
- Average True Range (ATR)
- SHIP 0.25
- LCTX 0.05
- MACD
- SHIP 0.04
- LCTX 0.02
- Stochastic Oscillator
- SHIP 57.53
- LCTX 69.26
About SHIP Seanergy Maritime Holdings Corp.
Seanergy Maritime Holdings Corp is an international shipping company that provides marine dry bulk transportation services through the ownership and operation of dry bulk vessels. It generates a majority of its revenue from the vessels. The company's fleet of vessels includes Fellowship, Championship, Partnership, Knightship, Lordship, Gloriuship, Leadership, Geniuship, Premiership, and Squireship, among others.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.